Adial制药公司报告EPS损失0.59美元,协商一致估计损失0.20美元,而7月短息增加92.5%。 Adial Pharmaceuticals reported a $0.59 EPS loss, missing consensus estimate by $0.20, while short interest increased by 92.5% in July.
Adial Pharmaceuticals（纳斯达克股票代码：ADIL）是一家专门从事成瘾和疾病治疗的临床阶段生物制药公司，报告称本季度每股收益亏损0.59美元，低于市场预期的0.39美元0.20美元。 Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical firm specializing in addiction & disorder treatments, reported a $0.59 EPS loss for the quarter, falling short of the consensus estimate of $0.39 by $0.20. 其主导产品AD04正处于酒精使用紊乱治疗的第三阶段临床试验阶段。 Its lead product, AD04, is in Phase III clinical trials for alcohol use disorder treatment. 股票交易额为0.97美元,50天SMA为1.12美元,200天SMA为1.40美元。 Shares traded at $0.97, with a 50-day SMA of $1.12 and a 200-day SMA of $1.40. 7月份空头股数增加了92.5%，其中7.2%的股票被做空。 Short interest increased by 92.5% in July, with 7.2% of shares shorted.